Feifei Na

1.1k total citations
33 papers, 618 citations indexed

About

Feifei Na is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Feifei Na has authored 33 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 14 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Feifei Na's work include Cancer, Hypoxia, and Metabolism (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Lung Cancer Research Studies (5 papers). Feifei Na is often cited by papers focused on Cancer, Hypoxia, and Metabolism (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Lung Cancer Research Studies (5 papers). Feifei Na collaborates with scholars based in China and United States. Feifei Na's co-authors include Jianxin Xue, You Lü, Lei Deng, Cong Li, Jingwen Wang, Chong Chen, Jingyao Chen, Jie Lan, Xiawei Wei and Ke Men and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Feifei Na

30 papers receiving 613 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Feifei Na China 14 224 210 166 124 114 33 618
Mitsunori Higuchi Japan 14 250 1.1× 126 0.6× 275 1.7× 108 0.9× 170 1.5× 77 654
Weibing Wu China 15 257 1.1× 333 1.6× 77 0.5× 91 0.7× 66 0.6× 41 638
Wenqing Wang China 15 252 1.1× 205 1.0× 213 1.3× 61 0.5× 39 0.3× 76 632
Adnan Ali United Kingdom 12 273 1.2× 171 0.8× 136 0.8× 66 0.5× 34 0.3× 36 624
Jixian Liu China 14 221 1.0× 405 1.9× 185 1.1× 36 0.3× 108 0.9× 32 751
Emilio Francesco Giunta Italy 15 174 0.8× 210 1.0× 386 2.3× 35 0.3× 96 0.8× 61 646
Carla M. van Herpen Netherlands 14 146 0.7× 195 0.9× 325 2.0× 45 0.4× 113 1.0× 27 608
Sabrina Rossi Italy 19 403 1.8× 155 0.7× 611 3.7× 177 1.4× 61 0.5× 55 899
Kimihiro Ito Japan 12 142 0.6× 185 0.9× 156 0.9× 60 0.5× 57 0.5× 26 482
Deyun Feng China 16 88 0.4× 376 1.8× 216 1.3× 59 0.5× 78 0.7× 46 702

Countries citing papers authored by Feifei Na

Since Specialization
Citations

This map shows the geographic impact of Feifei Na's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feifei Na with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feifei Na more than expected).

Fields of papers citing papers by Feifei Na

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feifei Na. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feifei Na. The network helps show where Feifei Na may publish in the future.

Co-authorship network of co-authors of Feifei Na

This figure shows the co-authorship network connecting the top 25 collaborators of Feifei Na. A scholar is included among the top collaborators of Feifei Na based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feifei Na. Feifei Na is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pan, Xiangyu, Feifei Na, & Xuelan Chen. (2024). Deciphering transcriptional bursts and enhancer dynamics: Advancing cancer therapeutics through single‐cell global run‐on sequencing. SHILAP Revista de lepidopterología. 3(3). 1 indexed citations
3.
4.
You, Liting, Feifei Na, Jiajia Song, et al.. (2023). Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors. European Journal of Cancer. 184. 124–136. 13 indexed citations
5.
6.
Zheng, Jianan, Xiangyu Pan, Zhixin Zhang, et al.. (2023). DNMT3AR882H accelerates angioimmunoblastic T-cell lymphoma in mice. Oncogene. 42(23). 1940–1950. 11 indexed citations
7.
Zheng, Yue, et al.. (2023). Cranial radiation therapy with hippocampus avoidance in lung cancer treatment: systematic review and meta-analysis. Frontiers in Oncology. 13. 1268754–1268754. 1 indexed citations
8.
You, Liting, et al.. (2023). Diverse regulated cell death modes predict the immune microenvironment and drug sensitivity in lung adenocarcinoma. Journal of Cellular Physiology. 238(11). 2570–2585. 1 indexed citations
9.
You, Liting, Jin Li, Feifei Na, et al.. (2023). Immunogenetic polymorphisms predict therapeutic efficacy and survival outcomes in tumor patients receiving PD-1/PD-L1 blockade. International Immunopharmacology. 121. 110469–110469. 2 indexed citations
10.
Liu, Caihong, Wei Wei, Letian Yang, et al.. (2023). Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Frontiers in Immunology. 14. 1173952–1173952. 15 indexed citations
11.
12.
Chen, Jingyao & Feifei Na. (2022). Organoid technology and applications in lung diseases: Models, mechanism research and therapy opportunities. Frontiers in Bioengineering and Biotechnology. 10. 1066869–1066869. 14 indexed citations
13.
Pan, Xiangyu, Jian Wang, Linjie Guo, et al.. (2022). Identifying a confused cell identity for esophageal squamous cell carcinoma. Signal Transduction and Targeted Therapy. 7(1). 122–122. 34 indexed citations
14.
Chen, Jingyao, Hongling Peng, Siqi Dai, et al.. (2020). An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway. Cancer Gene Therapy. 28(1-2). 112–125. 32 indexed citations
15.
Fang, Chunju, Fei Mo, Min Luo, et al.. (2020). Oxidized mitochondrial DNA sensing by STING signaling promotes the antitumor effect of an irradiated immunogenic cancer cell vaccine. Cellular and Molecular Immunology. 18(9). 2211–2223. 73 indexed citations
16.
Yin, Limei, Jianxin Xue, Feifei Na, et al.. (2018). PDGFR-β inhibitor slows tumor growth but increases metastasis in combined radiotherapy and Endostar therapy. Biomedicine & Pharmacotherapy. 99. 615–621. 11 indexed citations
17.
Chen, Baoqing, Feifei Na, Hui Yang, et al.. (2017). Ethyl pyruvate alleviates radiation-induced lung injury in mice. Biomedicine & Pharmacotherapy. 92. 468–478. 28 indexed citations
18.
Gao, Hui, Jianxin Xue, Lin Zhou, et al.. (2015). Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells. Cancer Letters. 365(1). 79–88. 21 indexed citations
19.
20.
Li, Cong, H. Lu, Feifei Na, et al.. (2013). Prognostic Role of Hypoxic Inducible Factor Expression in Non-small Cell Lung Cancer: A Meta-analysis. Asian Pacific Journal of Cancer Prevention. 14(6). 3607–3612. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mitsunori Higuchi Breakdown of academic impact, for papers by Weibing Wu Breakdown of academic impact, for papers by Wenqing Wang Breakdown of academic impact, for papers by Adnan Ali Breakdown of academic impact, for papers by Jixian Liu Breakdown of academic impact, for papers by Emilio Francesco Giunta Breakdown of academic impact, for papers by Carla M. van Herpen Breakdown of academic impact, for papers by Sabrina Rossi Breakdown of academic impact, for papers by Kimihiro Ito Breakdown of academic impact, for papers by Deyun Feng
Rankless by CCL
2026